Steroid 21-hydroxylase deficiency is a major cause of congenital adrenal hyperplasia and is caused by genetic impairment of this enzyme. Since approximately 80% of cases are caused by point mutations of the CYP21B (CYP21A2) gene, whereas the remaining 20% are due to deletion of this gene, we used the polymerase chain reaction single strand conformation polymorphism technique for rapid and accurate diagnosis of this disease. Of 23 patients examined, 1 had a hemizygous CYP21B gene. 18 patient's genes localized their harmful mutations or deletion on both the alleles, while 4 of them found their causative mutations on one of the two alleles, and 1 failed to find any responsible mutation. All the mutations (four nucleotide substitutions) detected are also found in the CYP21A (CYP21A1) pseudogene. A mutation at the intron 2 site is most prevalent in both salt-wasting and simple virilizing forms of the disease, and accounts for 37% of the patient's genes (17/46). Pedigree analysis of these mutations revealed that the mutations (at least four of them) occurred de novo at a considerable frequency on both the paternally and maternally inherited chromosomes. This result could explain occasional discordance of the diagnosis using HLA typing with the clinical symptoms. (CYP21A2) gene, whereas the remaining 20% are due to deletion of this gene, we used the polymerase chain reaction single strand conformation polymorphism technique for rapid and accurate diagnosis of this disease. Of 23 patients examined, 1 had a hemizygous CYP21B gene. 18 patient's genes localized their harmful mutations or deletion on both the alleles, while 4 of them found their causative mutations on one of the two alleles, and 1 failed to find any responsible mutation. All the mutations (four nucleotide substitutions) detected are also found in the CYP21A (CYP21A1) pseudogene. A mutation at the intron 2 site is most prevalent in both salt-wasting and simple virilizing forms of the disease, and accounts for 37% of the patient's genes (17/46). Pedigree analysis of these mutations revealed that the mutations (at least four of them) occurred de novo at a considerable frequency on both the paternally and maternally inherited chromosomes. This result could explain occasional discordance of the diagnosis using HLA typing with the clinical symptoms. (J. Clin. Invest. 1993. 92:2182-2190.) Key words: congenital adrenal hyperplasia. 21-hydroxylase deficiency. polymerase chain reaction * single strand conformation polymorphism * de novo mutation
Introduction
Congenital adrenal hyperplasia (CAH)' is one of the most common forms ofinborn metabolism error. Steroid 21 -hydroxylase deficiency accounts for 90-95% of CAH cases (1) (2) (3) and occurs at a frequency of 1 in 15,000 births (3, 4) . The symptoms of this disease are heterogeneous and are classified into three different clinical phenotypes: salt wasting (SW), simple virilizing (SV), and nonclassical (NC) forms. SW is the most severe form, in which cortisol and aldosterone synthesis is blocked, resulting in renal salt loss due to the lack of aldosterone and virilization due to accumulated adrenal androgen. SV, a less severe form, shows defective synthesis of only glucocorticoid with prominent features of virilization and sexual precocity (5, 6) . NC is a milder form than the two others, but is extremely prevalent and characterized by the late onset of excessive androgen (7, 8) . The clinical symptoms of this genetic disease may suggest different degrees of deficiency in steroidogenesis. Recent studies on the effects of various mutations in CYP2 1 activity and their distribution in the patient's genomes suggest that the three symptoms are somehow related to the degrees of the attenuated activities of mutated gene products (9, 10) .
In the human genome, there are two genes, CYP21A (CYP2 lAlP) and CYP21B (CYP2 IA2), each of which is located adjacent to one of the two genes for the fourth component of the complement, C4A and C4B, in the class III region of HLA complex. Ofthe two genes, CYP2 lB encodes an active enzyme, while CYP2 IA is a pseudogene with nine deleterious mutations (9) (10) (11) (12) .
DNA blot analysis using mutation-specific DNA probes or cloning and sequencing of the patient's genomic DNAs revealed that 15 -20% ofthe cases result from deletion ofthe TaqI 3.7-kb band of the CYP2 l B gene, and the remaining 80-85% of the cases are caused by point mutations in the CYP2 lB genes (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Interestingly, almost all the mutations identified so far in the patient's CYP2 l B genes are deleterious mutations found in the pseudogene (CYP2 IA gene). As suggested previously, these mutations are, most likely, products of gene conversion and/or homologous recombination events between the CYP2B and CYP2 IA genes, resulting in a high frequency of this genetic disease (13) (14) (15) (16) .
To further extend our study on the genetic deficiency ofthe CYP21 gene, we introduced the methods of PCR and single strand conformation polymorphism (SSCP) for accurate and rapid analysis of the patient's genomic DNAs (23-26). Here we report the usefulness of these methods for the diagnosis of genetic 2 1-hydroxylase deficiency and frequent generation of the defective CYP2 lB genes in the genetic transmission process revealed by family studies.
DNA blot hybridization. Genomic DNA samples were prepared from blood leukocytes by a standard procedure (27) . DNA was digested with the restriction endonuclease TaqI or Bgl II. The digests were subjected to 1.0% agarose gel electrophoresis and analyzed by the DNA blot analysis (28) . The hybridization probe used was the 3. 1 -kb EcoRIBamHI genomic fragment, which was labeled with [32P]ATP by nick translation. Filters were hybridized and washed under conditions described previously ( 13 ) . Then they were autoradiographed and hybridization signals were quantitated by densitometry using densitorol (DM-303; Advantec, Los Angeles, CA).
Nucleotide sequence analysis. The nucleotide sequence of the CYP2 lB gene from genomic DNA was determined directly with the PCR products by the chain termination method using appropriate sequencing primers. For the first PCR reaction followed by SSCP and direct sequencing analyses, the following primer pairs were used: A-B, C-D, and E-F (Table II) extension) without labeling, and the amplified products were purified on 1.0% agarose gel. The purified fragments were reamplified using a primer pair of I-J (Table II) for detection of the nonsense mutation in exon 8. For detection ofArg to Trp mutation in exon 8, the purified fragments were reamplified using a primer pair of K-L (Table 2) In our small group of patients the frequency of the gene deletion seems lower than the statistics reported previously. Generally speaking, the population ofthe deletion mutation in Japan seems to be lower than those reported in the United States ( 10, 15, 18, 19) , as we also reported its lower incidence in another group of CYP21 deficiency (9, 13 Table I . Only four of the deleterious mutations that are present in the pseudogene (CYP2 IA) were found as responsible ones in (29) (30) (31) (32) . PCR products were labeled by using 32P-labeled primers or deoxynucleotide. The labeled products were heat denatured and subjected to electrophoresis on nondenaturing polyacrylamide gel. Under these conditions the electrophoretic mobility ofsingle-stranded DNA is affected by their nucleotide sequence and the temperature of electrophoresis (23) (24) (25) (26) .
PCR-SSCP analysis ofthe intron 2 mutation shows several bands of different mobilities, as shown in Fig. 2 . Three bands were seen in patients 1, 6, 7, and 8, and seemed to indicate the heterozygosity, while patients 2, 3, 4, and 5 had two bands, indicative of the homozygosity (23-26). Then, this portion of the CYP2 lB genes was subjected to direct sequencing to determine the nucleotide changes responsible for different mobilities of these bands. In patients 4 and 5, only G mutation was found, indicating either homozygosity (patient 4) or hemizygosity (patient 5) in this region, while patients 1, 6, 7, and 8 were found to be heterozygous for the mutant G and normal A. Furthermore, sequence analysis revealed that another nucleotide variation occurred in exon 3: Lys(AAG) to Arg(AGG) at codon 102. The substitution of Lys to Arg is known to be neutral for the enzyme activity (19, 22) . Thus, the PCR-SSCP method proved to be useful for diagnosis ofthe intron 2 mutation. The remaining 15 patient's DNAs were also analyzed by PCR-SSCP with results shown in Table I .
For detection ofthe exon 4 mutation we used a primer pair of G-H in Table II Fig. 1 . Position indicates the nucleotide number as described previously (10) . Strategy for PCR-SSCP analysis was described in detail in Methods.
PCR-SSCP analysis we could diagnose that patients 2 and 3 were homozygous for the exon 4 mutation, while patients 4, 5, and 9 did not carry this mutation. Fig. 4 shows the results ofPCR-SSCP analysis with the exon 8 region containing two mutations: CAG (codon 318) to TAG and CGG (codon 356) to TTG. To obtain a clear separation of electrophoretic bands, two sets of primers were used, respectively, for the two mutations. Taken together with the result of the direct sequencing, the PCR-SSCP analysis with the region containing codon 318 (Fig. 4 A) shows that patients 11 and 16 are normal homozygotes in this region, while patients 12, 13, and 14 are mutant homozygotes and patient 15 is a heterozygote. The lower strands ofthese normal and mutant DNA fragments were not separated well in this and other attempts. Fig. 4 B shows the results with the region containing codon 356. Patients 1 1, 14, 15, and 16 are normal homozygotes in this region, while patients 12 and 13 are a mutant homozygote and a heterozygote, respectively, in this region.
All these results clearly indicate that the PCR-SSCP provides a rapid and sensitive diagnosis for a single mutation in CYP2 1 deficiency genes. fragments in Fig. 3 Fig. 5 . In DNA blot analysis shown in Fig. 5 A, the intensity ofthe 3.7-kb TaqI and 10-kb BglII bands demonstrated no gross alternation or deletion in either of the two CYP2 lB genes in the patient genome as well as those ofthe parents (densitometric analysis showed that the ratios in the band intensity of 3.7 and 3.2 kb are 1.0:1.0, 1.0:1.3, and 1.0:1.3 for I-1, 1-2, and II-1, respectively, and that those of 10 and 12 kb are 1:1 for all the family members). The entire sequence of the CYP2 lB gene of the patient was then amplified by a series of the primer pairs as described in Methods and subjected to the direct sequencing and SSCP analysis. The region containing the responsible mutation was amplified by a primer pair of C-B. To amplify equally the sequences of the two alleles of the CYP2 lb gene by the C-B primer, the sequences ofparental as well as patient's genes containing the C and B primer sites were first amplified by primer pairs, A-B and C-D, respectively, and confirmed by the direct sequencing. Since two mutation sites (intron 2 and codon 102) are included in this region, as described in Fig. 2 , electrophoretic patterns ofSSCP appear to be a little complex (I-1 is a homozygote with A at intron 2 [655] and G at codon 102, 1-2 is a heterozygote with G and A at intron 2 and G and A at codon 102, respectively, and 11-1 is a homozygote with G at intron 2 and G at codon 102) as seen in Fig. 5 B. The maternal genotype shows heterozygosity for the intron 2 site (A and G), while the paternal is a normal homozygote for the site of the intron 2 mutation, suggesting that the mutation occurred de novo on the paternally transmitted chromosome. The direct sequencing analysis (Fig. 5 C) of the concerned region confirmed the above suggestion. The HLA typing and DNA fingerprinting using the minisatellite myoglobin 33-repeated probe (35) (data not shown) also corroborated the family relations. The same analyses were carried out with patient 7. The intron 2 mutation, G, was generated de novo on the maternally inherited CYP2 lB gene (Tables I and HI) , while the paternally inherited gene carried the exon 4, T to A mutation (36) . The compound heterozygous mutations result in the SV type of CYP2 l B deficiency.
Pedigree analysis of the nonsense mutation in exon 8 was also performed and the results are summarized in Table III . De novo mutations were also observed at this site of patients 12 and 14. Representative analyses ofpatient 12's family are demonstrated in Fig. 6 . The maternal genotype shows heterozygosity in this region, while the paternal is a normal homozygote at the exon 8 site. DNA blot analysis of the genomic DNA using TaqI and BglII enzymes showed no deletion of the two allelic CYP2 lB genes in the patient and the parental genomes as shown in Fig. 6 A. The sequence identity used for I and J primers in the patient and parental genes was also confirmed by the direct sequencing. These results strongly suggested that the mutant homozygosity at the exon 8 mutation site of the patient was not due to unilateral amplification of one of the two allelic CYP2 lB genes, but to the de novo mutation C to T on the paternally transmitted chromosome. The HLA typing Table III Numbers of patients correspond to those in Table I . CYP21B gene copy estimated on the basis of intensity of 3.7-and 3.2-kb TaqI, 10-and 12-kb BglII restriction fragments. +/+, inherited chromosome is determined by a family study; +/0, a maternaly inherited chromosome is deleted; +/-, mutation present in paternal gene/no mutation in maternal gene; -/+, no mutation in paternal gene/mutation present in maternal gene; ++, +-, --, family study was not done. * De novo mutation in the paternally or maternally transmitted chromosome. and DNA fingerprinting using a minisatellite myoglobin 33-repeated probe (35) (data not shown) confirmed the family relation of the subjects examined. De novo mutation during the hereditary process was not only found at the two mutation sites, as described, but also at the exon 4 site (Ile to Asn) (data not shown).
Discussion
Ofthe high incidence ofcongenital steroid 2 1 -hydroxylase deficiency, about c 20% is accounted for by the deletion of the 4-A,G analysis. PCR-SSCP screening demonstrated that patient II-1 was homozygous for this mutation. In this family, the mother of I-2 showed a b and c pattern in Fig. 2 , therefore, she was diagnosed heterozygous for this mutation. However, the father of I-I showed an a pattern in Fig. 2 Arrows point to the C to T transition site at the first nucleotide of codon 318. 11-1 is homozygous for this mutation. In the 1-2 sequence ladder, the normal C and mutant T are at this position. In the I-1, only normal C nucleotide is present.
reported by Morel et al. ( 16) The PCR products along the entire sequences of the 23 patient's CYP2 lB genes were subjected to SSCP analysis or to direct sequencing. As summarized in Table I 4 , and exon 8 Gln to nonsense) occur at a considerable frequency, although the number of the examined cases is very limited. In three of the four cases reported, the de novo mutations ofthe patients occurred at the same sites ofthe allelic gene as that ofthe carrier parent, while the remaining one was generated at a different site. Although it remains to be studied whether de novo mutations are likely to occur at the same site of the allelic gene, it is interesting to note that homozygous mutations were observed in the patient's genomes at higher frequency than that calculated from random combinations of the frequency of those mutations (9, 10, 18, 19) . These de novo mutations appear to occur on both the maternally and paternally inherited chromosomes. Because they are all found in the pseudogene, these mutations are considered to be products ofthe gene conversion events but not to be bona fide point mutations, and explain at least in part the reason for high incidence ofthe genetic 2 1-hydroxylase deficiency. It remains to be studied what molecular mechanism frequently causes the gene conversion in this region or whether there is any specific sequence to facilitate the gene conversion event.
Close genetic linkage of the 2 1-hydroxylase deficiency of HLA complex has been known and HLA typing is now conventionally used for the prenatal diagnosis (5, 6, 34, 37) . It has been reported, however, that marked discordance between clinical features and diagnoses predicted from HLA typing was found in some families that have affected and unaffected siblings with the identical HLA haplotypes (38, 39) . Most ofsuch cases could be explained by de novo mutations due to gene conversion mechanism ( 10, 38) . Indeed, this is found to be the cases with patient 8's family, which has affected and unaffected siblings with identical HLA types (36) .
In general, while it has been revealed that -90% of the patient's genes with the genetic 2 1-hydroxylase deficiency can be explained by either the causative point mutations from the pseudogene or deletion mutations, no mutation responsible for the remaining 10% of the patient's genes has yet been identified. Recently, some mutations that were not present in the pseudogene were identified (40, 41 ) . It is possible that the remaining 10% ofpatient's genes have new mutations that do not exist in the pseudogene. To establish as perfect diagnosis by PCR-SSCP as possible, it is essential to identify the missing causative mutations for the remaining patient's genes.
